• Molecular NamePrazosin
  • SynonymPrazocin; Prazosin HCl; Prazosin Hydrochloride; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]
  • Weight383.408
  • Drugbank_IDDB00457
  • ACS_NO19216-56-9
  • Show 3D model
  • LogP (experiment)0.934
  • LogP (predicted, AB/LogP v2.0)1.36
  • pka6.5
  • LogD (pH=7, predicted)0.76
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.06
  • LogSw (predicted, AB/LogsW2.0)0.89
  • Sw (mg/ml) (predicted, ACD/Labs)0.25
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds4
  • TPSA106.95
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA sympatholytic drug used to treat high blood pressure (hypertension). It belongs to the class of alpha-adrenergic blockers, which lower blood pressure by relaxing blood vessels.
  • Absorption_value86.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability68.0
  • Protein binding97.0
  • Volume of distribution (VD)0.60 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPrimarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).
  • Half life2.9 h
  • ExcretionN/A
  • Urinary Excretion<4
  • Clerance3 ml/min/kg
  • ToxicityThe most frequent reactions associated with prazosin therapy are dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpations 5.3%, and nausea 4.9%
  • LD50 (rat)N/A
  • LD50 (mouse)N/A